MedTrace Logo

A Study of Olaparib and Durvalumab in Prostate Cancer

NCT03810105 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-04-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.

Conditions

Interventions

DRUG

Olaparib

Olaparib 300mg twice daily (600mg total daily dose)

DRUG

Durvalumab

Durvalumab 1500mg IV monthly

Sponsors & Collaborators

Principal Investigators

  • Karen Autio, MD, MsC · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-07
Primary Completion
2023-07-06
Completion
2023-07-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03810105 on ClinicalTrials.gov